文献速递乳腺癌

地诺单抗联合两种白蛋白结合型紫杉醇新辅助方案治疗原发性乳腺癌的疗效:GeparX 2×2 随机临床试验

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

GeparX 研究在 38 家德国中心纳入 780 例原发性乳腺癌患者,2×2 随机比较地诺单抗与否及两种白蛋白结合型紫杉醇方案。地诺单抗未提高 pCR 率(41.0% vs 42.8%,P=0.58);每周方案 pCR 率 44.9% vs 每 3 周方案 39.0%(P=0.06),但 3–4 级非血液学毒性更高(33.7% vs 24.1%,P=0.004)。

要点

  • 地诺单抗加入蒽环/紫杉类新辅助化疗未提高 pCR 率,各亚型一致。
  • 每周白蛋白结合型紫杉醇 pCR 率 44.9% vs 每 3 周方案 39.0%,差异未达统计学显著(P=0.06)。
  • 每周方案 3–4 级非血液学毒性更高(33.7% vs 24.1%,P=0.004)。

核心结论

  • 地诺单抗加入蒽环/紫杉类新辅助化疗未提高 pCR 率。
  • 每周 125 mg/m2 白蛋白结合型紫杉醇较第 1、8 天每 3 周方案总体及 TNBC 中显著提高 pCR 率,但毒性更高。

研究设计与样本

  • GeparX 为多中心、前瞻性、开放标签、2b 期、2×2 随机临床试验,由 GBG 和 AGO-B 于 2017 年 2 月至 2019 年 3 月在 38 家德国中心开展。
  • 分析数据集于 2020 年 9 月 4 日锁定,分析于 2020 年 11 月 13 日完成。
  • 共随机 780 例女性(n=779)和男性(n=1)患者,中位(范围)年龄 49.0(22–80)岁,分入 4 个治疗组。
  • 患者为单侧或双侧原发性乳腺癌,分期 cT2-cT4a-d 或 cT1c,伴临床淋巴结阳性或病理淋巴结阳性或 HR 阴性,或 Ki-67 增殖指数大于 20%,或 ERBB2(原 HER2)阳性。

主要发现

  • 地诺单抗组 pCR(ypT0 ypN0)率 41.0%(90%CI 37%–45%)vs 无地诺单抗组 42.8%(90%CI 39%–47%)(P=0.58),与乳腺癌亚型无关。
  • 每周白蛋白结合型紫杉醇 pCR 率 44.9%(90%CI 41%–49%)vs 第 1、8 天每 3 周方案 39.0%(90%CI 35%–43%)(P=0.06),在 α=0.10 显著性水平下显著。
  • 亚组中仅 TNBC 的两种白蛋白结合型紫杉醇方案 pCR 率差异显著(60.4% vs 50.0%;P=0.06)。
  • 3–4 级毒性反应在地诺单抗组与无地诺单抗组间无差异。
  • 每周白蛋白结合型紫杉醇组 3–4 级非血液学毒性更高(33.7% vs 24.1%;P=0.004)。

关键数值与推荐

  • 地诺单抗 120 mg 皮下注射,每 4 周一次,共 6 个周期。
  • 白蛋白结合型紫杉醇 125 mg/m2 每周一次共 12 周,或第 1、8 天每 3 周一次共 4 个周期(8 剂)。
  • 后续表柔比星/环磷酰胺 90/600 mg/m2 共 4 个周期(每 2 周或每 3 周)。
  • TNBC 给予卡铂;ERBB2 阳性乳腺癌给予曲妥珠单抗生物类似药 ABP980 联合帕妥珠单抗(ERBB2 阳性子研究)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear. OBJECTIVE: To determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy (NACT) increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in the NACT setting. DESIGN, SETTING, AND PARTICIPANTS: The GeparX was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. The analysis data set was locked September 4, 2020; analysis was completed November 13, 2020. Patients had unilateral or bilateral primary BC, stage cT2-cT4a-d or cT1c, with either clinically node-positive or pathologically node-positive or HR-negative disease, or Ki-67 proliferation index greater than 20%, or ERBB2 (formerly HER2)-positive BC. INTERVENTIONS: Patients were randomized to receive or not receive denosumab, 120 mg subcutaneously every 4 weeks for 6 cycles, and either nab-paclitaxel, 125 mg/m2 weekly for 12 weeks or days 1 and 8 every 3 weeks for 4 cycles (8 doses), followed by 4 cycles of epirubicin/cyclophosphamide, 90/600 mg/m2 (every 2 weeks or every 3 weeks). Carboplatin was given in triple-negative BC (TNBC), and trastuzumab biosimilar ABP980 plus pertuzumab was given in ERBB2-positive BC (ERBB2-positive substudy). MAIN OUTCOMES AND MEASURES: The primary outcome was pCR rates between arms for each randomization. RESULTS: A total of 780 female (n = 779) and male (n = 1) patients (median [range] age, 49.0 [22-80] years) were randomized to the 4 treatment groups. The pCR (ypT0 ypN0) rate was 41.0% (90% CI, 37%-45%) with denosumab vs 42.8% (90% CI, 39%-47%) (P = .58) without denosumab, irrespective of BC subtype. Nab-paclitaxel weekly resulted in a significantly (significance level of α = .10) higher pCR rate of 44.9% (90% CI, 41%-49%) vs 39.0% (90% CI, 35%-43%) (P = .06) with nab-paclitaxel days 1 and 8 every 3 weeks. The pCR rates for nab-paclitaxel schedules in subgroups were only significantly different for TNBC (60.4% vs 50.0%; P = .06). Grade 3 to 4 toxic effects did not differ with or without denosumab. Nonhematologic toxic effects of grade 3 to 4 were higher with nab-paclitaxel weekly (33.7% vs 24.1%; P = .004). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, denosumab added to anthracycline/taxane-based NACT did not improve pCR rates. Nab-paclitaxel at a dosage of 125 mg/m2 weekly significantly increased the pCR rate compared with the days 1 and 8, every-3-weeks schedule overall and in TNBC, but generated higher toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02682693.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Blohmer JU, Link T, Reinisch M, et al. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35588050. doi:10.1001/jamaoncol.2022.1059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。